ELC-301

Gothenburg, April 4, 2025 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on its proprietary commercial technology platform iTANK, today announced that the company’s Chief Scientific Officer, Professor Magnus Essand, has been invited to speak at the Swedish Cancer Research Meeting (SCRM) 2025 in Malmö on May 22. SCRM is Sweden’s largest cancer research meeting, held every other year, where prominent international researchers are also invited. At SCRM2025, leading representatives from academia, healthcare, and industry will gather to exchange knowledge, present new research findings, and foster collaboration. The goal is to strengthen Sweden’s cancer research ecosystem and create the conditions for joint efforts that can lead to improved treatments and a deeper understanding of cancer. Magnus Essand, one of the co-founders of Elicera Therapeutics and Professor of Gene Therapy at Uppsala University, will participate as a speaker at SCRM2025. His presentation, titled "Novel cell and gene therapies for the treatment of cancer – The Uppsala experience", will highlight the company’s progress in developing novel cell and gene therapies for cancer treatment. During his talk, Professor Essand will present Elicera Therapeutics’ CAR T-cell program and the company’s proprietary platform technology, iTANK, which is used to arm CAR T-cells to trigger a broad immune activation against cancer. He will also present preliminary efficacy data from cohort 1 of the ongoing CARMA study, which evaluates the safety and efficacy of ELC-301 – the company’s iTANK-armed CAR T-cell therapy targeting B-cell lymphoma. In light of this, Elicera has decided not to present the cohort 1 data at the ISCT conference, in order to generate greater impact at SCRM2025. This decision also enables the inclusion of data from a longer follow-up period, which is expected to provide a more informative and valuable data set. For further information, please contact: Jamal El-Mosleh, CEO, Elicera Therapeutics AB (publ) Phone: +46 (0) 703 31 90 51 jamal.elmosleh@elicera.com Certified Advisor Mangold Fondkommission AB About the CARMA Study CARMA is a phase I/IIa clinical study evaluating the safety and efficacy of the CAR T-cell therapy ELC-301 in the treatment of patients with B-cell lymphoma. The study is divided into a dose-escalation phase (phase I) and a dose-expansion phase (phase IIa). Phase I primarily aims to establish the optimal dose and safety profile in up to 12 patients, while phase IIa will further evaluate the efficacy of the maximum tolerated dose in an additional six patients. Phase I is planned to include three cohorts (dosing groups), with three patients in the first and second cohorts, and six patients in the third dcohort, who are expected to receive the maximum tolerated dose. The CARMA study is being conducted at Uppsala University Hospital and Karolinska University Hospital in Huddinge. About ELC-301 ELC-301 is a fourth-generation CAR T-cell therapy targeting the CD20 antigen, armed with the company’s iTANK platform to activate a broader and more comprehensive parallel immune response against cancer. CAR T-cells are a form of cell therapy created by genetically modifying a patient’s T-cells to express a synthetic receptor (chimeric antigen receptor, CAR). This receptor is specifically designed to target a single tumor antigen—a molecule visible on the surface of cancer cells—and enables the T-cells to locate, bind to, and destroy the cancer cells. About the iTANK platform The iTANK technology platform has been developed for arming and enhancing CAR T-cells to meet two of the major challenges CAR T-cell therapies face in the treatment of solid tumors: a very diverse set of tumor antigen targets and a very hostile tumor microenvironment. The technology is used to incorporate a transgene into CAR T-cells encoding a neutrophil activating bacterial protein (NAP). NAP secreted from the CAR(NAP) T-cells has been shown to be able to enhance the function of CAR T-cells and importantly activating a parallel bystander immune response against the cancer via CD8+ killer T-cells. This is expected to lead to a broad attack against most antigen targets on cancer cells. The iTANK platform is used to enhance the company’s own CAR T-cells but can also be universally applied to other CAR T-cell therapies under development. Proof-of-concept data was published in Nature Biomedical Engineering in April 2022. The publication, titled “CAR T cells expressing a bacterial virulence factor triggers potent bystander antitumor responses in solid cancers” (DOI number: 10.1038/s41551-022-00875-5) can be found here: https://www.nature.com/articles/s41551-022-00875-5. More information about iTANK platform is available here: https://www.elicera.com/technology About Elicera Therapeutics AB Elicera Therapeutics AB (publ) has developed the patented gene technology platform iTANK that enables the arming of new and existing CAR T-cell therapies targeting aggressive and relapsing cancer forms. Elicera Therapeutics thereby addresses a well-defined and vast market. The company’s CAR T-cell therapies have shown a potent effect toward solid tumors which are recognized as particularly difficult to treat and constitute the majority of cancer cases. The company addresses a global multibillion market in cell therapy through its offering of non-exclusive licensing of the iTANK-platform to companies in the pharmaceutical industry. Elicera Therapeutics has four internal development projects in immune therapy that separately have the potential to generate substantial value through exclusive out-licensing agreements. The company’s share is traded on Nasdaq First North Growth Market. For additional information, visit www.elicera.com.

Gothenburg, February 12, 2025 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on its proprietary commercial technology platform iTANK, announces today that the company has received notification of a partial payment of EUR 500,000 from the European Innovation Council (EIC) under the framework of its Accelerator Programme. This represents the third payment in a four-part funding program. The remaining grant amount of EUR 375,000 is expected to be disbursed in 2026. The European Innovation Council's (EIC) Accelerator Programme aims to support innovative small companies through a funding program of up to EUR 2.5 million in grants, along with the possibility of strategic investments. Applications to the program are submitted under highly competitive conditions, with only 5% of applicant companies receiving funding. EIC awarded Elicera Therapeutics the grant to support the clinical development of its innovative cell therapy, ELC-301. The current EUR 500,000 disbursement has been granted following the company’s reported progress in the ongoing Phase I/IIa clinical study CARMA. The fourth and final payment of EUR 375,000 is expected in 2026. “We are pleased with the continued funding provided through the European Innovation Council's Accelerator Programme. The capital will be used for the further clinical development of ELC-301 in our ongoing Phase I/IIa CARMA study, where we have recently made promising observations in the treatment of B-cell lymphoma. We look forward to maintaining a strong dialogue with the agency and reporting additional data ahead of the fourth and final payment next year,” says Jamal El-Mosleh, CEO of Elicera Therapeutics. For further information, please contact: Jamal El-Mosleh, CEO, Elicera Therapeutics AB (publ) Phone: +46 (0) 703 31 90 51 jamal.elmosleh@elicera.com Certified Advisor Mangold Fondkommission AB About the CARMA Study CARMA is a phase I/IIa clinical study evaluating the safety and efficacy of the CAR T-cell therapy ELC-301 in the treatment of patients with B-cell lymphoma. The study is divided into a dose-escalation phase (phase I) and a dose-expansion phase (phase IIa). Phase I primarily aims to establish the optimal dose and safety profile in up to 12 patients, while phase IIa will further evaluate the efficacy of the maximum tolerated dose in an additional six patients. Phase I is planned to include three cohorts (dosing groups), with three patients in the first and second cohorts, and six patients in the third dcohort, who are expected to receive the maximum tolerated dose. The CARMA study is being conducted at Uppsala University Hospital and Karolinska University Hospital in Huddinge. About ELC-301 ELC-301 is a fourth-generation CAR T-cell therapy targeting the CD20 antigen, armed with the company’s iTANK platform to activate a broader and more comprehensive parallel immune response against cancer. CAR T-cells are a form of cell therapy created by genetically modifying a patient’s T-cells to express a synthetic receptor (chimeric antigen receptor, CAR). This receptor is specifically designed to target a single tumor antigen—a molecule visible on the surface of cancer cells—and enables the T-cells to locate, bind to, and destroy the cancer cells. About the iTANK platform The iTANK technology platform has been developed for arming and enhancing CAR T-cells to meet two of the major challenges CAR T-cell therapies face in the treatment of solid tumors: a very diverse set of tumor antigen targets and a very hostile tumor microenvironment. The technology is used to incorporate a transgene into CAR T-cells encoding a neutrophil activating bacterial protein (NAP). NAP secreted from the CAR(NAP) T-cells has been shown to be able to enhance the function of CAR T-cells and importantly activating a parallel bystander immune response against the cancer via CD8+ killer T-cells. This is expected to lead to a broad attack against most antigen targets on cancer cells. The iTANK platform is used to enhance the company’s own CAR T-cells but can also be universally applied to other CAR T-cell therapies under development. Proof-of-concept data was published in Nature Biomedical Engineering in April 2022. The publication, titled “CAR T cells expressing a bacterial virulence factor triggers potent bystander antitumor responses in solid cancers” (DOI number: 10.1038/s41551-022-00875-5) can be found here: https://www.nature.com/articles/s41551-022-00875-5. More information about iTANK platform is available here: https://www.elicera.com/technology About Elicera Therapeutics AB Elicera Therapeutics AB (publ) has developed the patented gene technology platform iTANK that enables the arming of new and existing CAR T-cell therapies targeting aggressive and relapsing cancer forms. Elicera Therapeutics thereby addresses a well-defined and vast market. The company’s CAR T-cell therapies have shown a potent effect toward solid tumors which are recognized as particularly difficult to treat and constitute the majority of cancer cases. The company addresses a global multibillion market in cell therapy through its offering of non-exclusive licensing of the iTANK-platform to companies in the pharmaceutical industry. Elicera Therapeutics has four internal development projects in immune therapy that separately have the potential to generate substantial value through exclusive out-licensing agreements. The company’s share is traded on Nasdaq First North Growth Market. For additional information, visit www.elicera.com.